TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06303310

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gaze Stability Exercises
Description: Group A ( Gaze Stability Exercise+ Routine Physical Therapy) Group A will receive gaze stability exercises consist of 5 structured components for 20 minutes and the routine physical therapy consisting of balance exercises of 20 minute for 5 days a week for 4 weeks.(16)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Optokinetic Exercises
Description: Group B (Optokinetic Exercises+Routine Physical Therapy) Group B will receive optokinetic exercises for 20 minutes and the routine physical therapy consisting of balance exercises of 20 minute for 5 days a week for 4 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine Physical Therapy
Description: Routine Physical Therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine Physical Therapy
Description: Routine Physical Therapy
Study: NCT05783375

Intervention type: OTHER
Group type: OTHER
Intervention: ADUNU program for delivery of RHD care services
Description: The ADUNU program will be deployed by the Ugandan Ministry of Health and the involved District Health Offices to include echocardiography integrated into primary healthcare to screen for RHD and a registry-based care system to keep patients linked to care and prophylaxis.
Study: NCT04571320

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Summer STRIPES
Description: See arm description.
Study: NCT06409949

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Muscle Oxygen
Description: Evaluation of calf muscle heme oxygen saturation

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Muscle Oxygen
Description: Evaluation of calf muscle heme oxygen saturation

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Serum MitoQ Level
Description: Evaluation of serum concentrations of MitoQ

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Serum MitoQ Level
Description: Evaluation of serum concentrations of MitoQ

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Needle Biopsy
Description: Needle biopsy of the calf muscle

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Needle Biopsy
Description: Needle biopsy of the calf muscle
Study: NCT04571320

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced School Services as Usual
Description: see arm description.
Study: NCT05172102

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: breathing exercise, Aerobic exercises
Description: 6 min of quiet breathing (3 sets of 2 min each), 6 min of diaphragmatic breathing (3 sets of 2 min each), 6 min of diaphragmatic breathing plus pursed-lips breathing (3 sets of 2 min each).
Study: NCT04277689

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Brain signal data collection
Description: Collection of speech related electrophysiological data at the time of DBS.
Study: NCT06098092

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Long-term non-invasive Blood pressure monitoring
Description: All measurements during the experiment include only non-invasive Blood pressure and Heart rate measurements. Measurements will be taken using a smartwatch attached to the wrist and a digital tonometer with a cuff placed on the other arm. Paired readings will be compared.
Study: NCT04716907

Intervention type: GENETIC
Intervention: Single-Nucleotide Polymorphisms (SNP) within the TCRA/D region
Description: DNA extraction from blood samples, PCR and Sequencing

Intervention type: BIOLOGICAL
Intervention: Blood sample
Description: Dosage of sj/βTREC ratio, lymphocytes, cytokines and chemokines.

Intervention type: BIOLOGICAL
Intervention: Blood sample
Description: Dosage of sj/βTREC ratio, lymphocytes, cytokines and chemokines.
Study: NCT05779007

Intervention type: DRUG
Intervention: Pirfenidone
Description: Pirfenidone

Intervention type: DRUG
Intervention: Nintedanib
Description: Nintedanib
Study: NCT04716907

Intervention type: DIAGNOSTIC_TEST
Intervention: CT Scan
Description: Thymus and lung imaging

Intervention type: DIAGNOSTIC_TEST
Intervention: CT Scan
Description: Thymus and lung imaging

Intervention type: BIOLOGICAL
Intervention: Bronchial fibroscopy
Description: Bronchoalveolar lavage in mechanically ventilated patients for dosage of recent thymic emigrants in lungs
Study: NCT06101095

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: Subcutaneous injection (SC) as per protocol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: SC injection as per protocol
Study: NCT06129175

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Neuroncell-EX
Description: Intravenous infusion of Neuroncell-EX (2 million UCMSCs per kg body weight) on day 1 and day 14 plus standard medical care.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous infusion of Placebo (normal saline) on day 1 and day 14 plus standard medical care.
Study: NCT05397431

Intervention type: DRUG
Intervention: Lanadelumab
Description: Lanadelumab 300 mg, subcutaneous injection every 2 weeks
Study: NCT05116878

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3
Description: One capsule orally twice daily beginning 3 days prior to clinical care surgical intervention and continuing 6 weeks post-operative

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One cellulose capsule orally twice daily beginning 3 days prior to clinical care surgical intervention and continuing 6 weeks post-operative
Study: NCT05246566

Intervention type: OTHER
Intervention: Routine care
Description: The investigator takes care of the patient according to the protocol in force in his department and decides on the final orientation of the patient (transfer to intensive care unit/ICU, hospitalization or home discharge).~No recommendations or instructions are given to the investigators. Each investigator is free to decide on his care and the terms of transfer, hospitalization and discharge.
Study: NCT06557772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlitelimab
Description: Pharmaceutical form: Injection solution Route of administration: SC injection
Study: NCT04502433

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CUROSURF® (poractant alfa)
Description: Three administrations with a 24 hours dosing interval.~Each endotracheal (ET) administration 1, 2, and 3 consisted of poractant alfa bolus:~30mg /kg (Lean Body Weight-LBW) = 0.375ml /kg LBW, diluted with normal saline up to 2ml /kg LBW.
Study: NCT06557772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlitelimab
Description: Pharmaceutical form: Injection solution Route of administration: SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlitelimab
Description: Pharmaceutical form: Injection solution Route of administration: SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlitelimab
Description: Pharmaceutical form: Injection solution Route of administration: SC injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: Injection solution Route of administration: SC injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: Injection solution Route of administration: SC injection

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: SIGE
Description: Pharmaceutical form: Capsule Route of administration: Oral

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: SIGE
Description: Pharmaceutical form: Capsule Route of administration: Oral

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Gluten-free product (GFP)
Description: Pharmaceutical form: Capsule Route of administration: Oral

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Gluten-free product (GFP)
Description: Pharmaceutical form: Capsule Route of administration: Oral

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Gluten-free product (GFP)
Description: Pharmaceutical form: Capsule Route of administration: Oral

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Gluten-free product (GFP)
Description: Pharmaceutical form: Capsule Route of administration: Oral
Study: NCT06312137

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sacituzumab tirumotecan
Description: Sacituzumab tirumotecan to be administered as 4mg/kg IV infusion q2w for up to 40 weeks

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Pembrolizumab to be administered 400mg by IV infusion q6w for up to 42 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab to be administered 400mg by IV infusion q6w for up to 42 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin is administered as 75 mg/m2 IV infusion q3w for up to 12 weeks as background treatment in neoadjuvant phase

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Pemetrexed will be administered in the neoadjuvant phase as 500 mg/m2 IV infusion q3w for up to 12 weeks as background treatment in participants with nonsquamous NSCLC.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine will be administered in the neoadjuvant phase as 1000 mg/m2 or 1250 mg/m2 IV infusion on day 1 and day 8 q3w for up to 24 weeks as background treatment in participants with squamous NSCLC.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin will be administered in the neoadjuvant phase as AUC 5 mg/mL/min or AUC 6 mg/mL/min IV infusion q3w for up to 12 weeks as background treatment.
Study: NCT06208696

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tomando control de su salud (Spanish Chronic Disease Self-Management)
Description: Tomando control de su salud (Spanish Chronic Disease Self-Management) is a culturally appropriate program developed in Spanish to support Hispanics patients to build confidence in their ability to manage their health. This intervention was developed by Lorig et al. at Stanford University and has been widely used by the Puerto Rico Department of Health since it is recommended by the CDC as an evidenced-based intervention for chronic disease management.
Study: NCT06312137

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel will be administered in the neoadjuvant phase as 175 mg/m2 or 200 mg/m2 IV infusion q3w for up to 12 weeks as background treatment.
Study: NCT06562595

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education Intervention
Description: Training will be provided to the participants, with the objective of determining the most accurate training method on HPV and cervical awareness.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education Intervention
Description: Training will be provided to the participants, with the objective of determining the most accurate training method on HPV and cervical awareness.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education Intervention
Description: Training will be provided to the participants, with the objective of determining the most accurate training method on HPV and cervical awareness.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education Intervention
Description: Training will be provided to the participants, with the objective of determining the most accurate training method on HPV and cervical awareness.
Study: NCT04971109

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TPOXX
Description: Study is based on Animal Regulatory Rule
Study: NCT06654401

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Transthoracic echocardiography
Description: Standard assessment of the parameters of the left atrium: size, volume, volume indices

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Transthoracic echocardiography
Description: Standard assessment of the parameters of the left atrium: size, volume, volume indices

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 24-hour ECG Monitor
Description: Assessment of cardiac arrhythmias according to 24-hour monitoring data

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: 24-hour ECG Monitor
Description: Assessment of cardiac arrhythmias according to 24-hour monitoring data

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electroanatomic mapping
Description: Intraoperative assessment of low voltage areas (potential fibrosis zones)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Electroanatomic mapping
Description: Intraoperative assessment of low voltage areas (potential fibrosis zones)
Study: NCT04950582

Intervention type: DIAGNOSTIC_TEST
Intervention: Spectral characteristics assessment
Description: Urine sample analysis for evidence of urinary tract infection
Study: NCT05528497

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VR+
Description: Use of a virtual reality helmet during ovocyte retrieval
Study: NCT04230395

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CAP
Description: 4-session combination Motivational Enhancement Therapy and Cognitive Behavioral Therapy alcohol reduction intervention. The intervention will also include 3 booster sessions.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: Provider advice to reduce alcohol use per recommended standard of clinical care, and referral to treatment as indicated
Study: NCT05021601

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bi-atrial ablation
Description: This intervention includes mitral valve surgery concomitant with left atrial ablation and right atrial ablation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Left atrial ablation
Description: This intervention includes mitral valve surgery concomitant with left atrial ablation alone.
Study: NCT05797675

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: prf + osseodensification
Description: prf+ osseodensification in close sinus lift
Study: NCT05841134

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Neoadjuvant treatment options:~Tislelizumab 200mg, intravenous infusion, D1, Q3W, a total of 4 cycles; Oxaliplatin 130mg/m2, intravenous infusion, D1, Q3W, 4 cycles in total; Capecitabine 1000mg/m2, orally twice in the morning and evening, D1-14, Q3W, 4 cycles in total;~Adjuvant treatment options:~Tislelizumab 200mg, intravenous infusion, Q3W;~± Chemotherapy method (researcher judges whether to add chemotherapy according to the comprehensive condition of the patient); Until disease progression or unacceptable toxicity, the maximum treatment time is 12 months.
Study: NCT06106633

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TriNaV
Description: Assess Pain Reduction and Ovarian Perfusion Following Uterine Fibroid Embolization Via Pressure-Enabled Drug Delivery With the TriNav Infusion System
Study: NCT05466838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PERT at discharge
Description: Starting dose 50,000 units lipase per meal with 3 meals planned per day and 25,000 units of lipase per snack with 2 snacks planned per day. Dose escalation 100,000 units lipase with meals and 50,000 units with snacks.
Study: NCT04971109

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: TPOXX Placebo
Description: Does not apply
Study: NCT05871970

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TARA-002
Description: All participants will receive up to 4 intracystic injections spaced approximately 6 weeks apart.
Study: NCT05466838

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Initiation of PERT if clinical symptoms of PEI develop or worsen. Starting dose 50,000 units lipase per meal with 3 meals planned per day and 25,000 units of lipase per snack with 2 snacks planned per day.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: Initiation of PERT if clinical symptoms of PEI develop or worsen. Starting dose 50,000 units lipase per meal with 3 meals planned per day and 25,000 units of lipase per snack with 2 snacks planned per day.
Study: NCT06683209

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Schocket scleral depressor
Description: Use of this instrument to examine one eye
Study: NCT05196776

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Portable, handheld point-of-care ultrasound device
Description: The patient will have an ultrasound performed using a handheld, portable device.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cart-based point-of-care ultrasound device
Description: The patient will have an ultrasound performed using a traditional cart-based model.
Study: NCT06565793

Intervention type: DEVICE
Intervention: Non Complex PCI
Description: The patient cohort included individuals who had been hospitalized with a diagnosis of either STEMI or non-STEMI. The procedure involved percutaneous coronary intervention (PCI) with the use of drug-eluting stents (DES).

Intervention type: DEVICE
Intervention: Complex PCI
Description: The patient cohort included individuals who had been hospitalized with a diagnosis of either STEMI or non-STEMI. The procedure involved complex percutaneous coronary intervention (PCI) with the use of drug-eluting stents (DES).This designation is applied to angioplasty procedures that meet at least one criterion for complexity. The complex angioplasty involved patients with unprotected left coronary common trunk (UT-PCI), the use of rotablator rotary atherectomy (ARota-PCI), the angioplasty of chronic coronary occlusion (CCO-PCI), or the angioplasty of a bifurcation lesion (CBL-PCI).The highly intricate angioplasty procedure was conducted on patients who met at least two criteria indicative of complexity.
Study: NCT06503185

Intervention type: BEHAVIORAL
Intervention: Prehabilitation
Description: The intervention is a home-based, multimodal exercise prehabilitation program. Exercise is prescribed in one-hour sessions, performed a minimum of three times per week for three weeks, consisting of: 1) strength training, 2) aerobic exercise and 3) flexibility. The intervention group will receive weekly phone calls to gauge adherence, suggest modifications, provide support and track any adverse events.
Study: NCT06250608

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulse oximeter, NIRSITX
Description: It is a device that non-invasively continuously monitors blood oxygen saturation (rSO2) in localized areas of the brain. This device is attached to patients with symptoms suspected of stroke or diagnosed with stroke to continuously monitor the level of oxygen supply to the brain.
Study: NCT05693948

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Other: Serum X
Description: Serum X contain arbutin and glutathione
Study: NCT04843020

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ION 682884
Description: Subcutaneous injection every month
Study: NCT06040931

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bronchoscopy
Description: Bronchoscopy and broncho-alveolar lavage (BAL) to assess neutrophilic count in BAL as a measurement of airway inflammation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bronchoscopy
Description: Bronchoscopy and broncho-alveolar lavage (BAL) to assess neutrophilic count in BAL as a measurement of airway inflammation
Study: NCT06683209

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Schocket scleral depressor
Description: Use of this instrument to examine one eye

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Josephberg-Besser
Description: Use of this instrument to examine one eye

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Josephberg-Besser
Description: Use of this instrument to examine one eye

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Cotton tip applicator
Description: Use of this instrument to examine one eye

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Cotton tip applicator
Description: Use of this instrument to examine one eye
Study: NCT06281457

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stimulus properties: task-defining feature
Description: The feature used to determine which stimulus feature to attend to will be varied across trials using a letter cue (M = motion-attend, C = color-attend, F = fixation-attend)
Study: NCT06532188

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hypno-ear-acupuncture
Description: 5 acupuncture permanent needles on ear acupuncture points according to the National Acupuncture Detoxification Association (NADA) protocol, needle retention after 7 days standardized medical hypnosis:~* Induction of a trance~* suggestions for calm and good sleep

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Hypno-ear-acupuncture
Description: 5 acupuncture permanent needles on ear acupuncture points inserted at non-specific points on the backside of the outer ear, needle retention after 7 days standardized sham hypnosis~- story without trance induction and suggestions
Study: NCT06693609

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EMP-01
Description: EMP-01 capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: EMP-01 Placebo
Description: EMP-01 placebo capsules
Study: NCT05332769

Intervention type: GENETIC
Intervention: FLIM parameters
Description: Cumulus samples (CCs) will be collected following the protocol on the day of oocyte pick up (OPU). CCs are frozen by the cryo-tech method, then stored in liquid nitrogen at -196oC. Information of CC samples and processed date/time is recorded. After all, samples are collected, they will be transferred to The Needleman Lab, Northwest Lab Building 359,52 Oxford Street Cambridge MA 02138 to measure mitochondria metabolism using FLIM.
Study: NCT04660539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: satralizumab
Description: Satralizumab will be administered by SC injection in the abdominal or femoral region at a dose of 120 mg (fixed dose) Q4W for up to 3 years

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azathioprine (AZA)
Description: Participants are permitted to use AZA during the study as background immunosuppressive treatment at a maximum dose of 3 milligram per kilogram per day (mg/kg/day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil (MMF)
Description: Participants are permitted to use MMF during the study as background immunosuppressive treatment at a maximum dose of 3000 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral corticosteroids
Description: Participants are permitted to use oral corticosteroids (prednisolone equivalent) during the study as background immunosuppressive treatment at a maximum dose of 15 mg/day